Navigation Links
Inscent, Inc. Receives Federal Grant to Develop Honeybee Repellents

IRVINE, Calif., April 28 /PRNewswire/ -- Inscent, Inc. has received a Small Business Innovative Research grant from the US National Science Foundation (NSF) to continue the testing and development of novel honeybee repellents using the proprietary Attenu high throughput assay system. The pioneering research performed by Inscent, Inc. has resulted in highly efficient processes that allow the rapid development of revolutionary insect control products suited for the modern age. Inscent's groundbreaking paradigm shift away from traditional insecticides and toward products based on behavior alteration of targeted species has been supported extensively by federal research grants and private industry funds. NSF reviewers described the honeybee repellent project as "fascinating" and "highly desirable," and new federal funding commences in July 2008.

Inscent, Inc. is designing environmentally responsible insect control products that will eclipse the current generation of insecticides. The company's latest efforts focus on the honeybee, Apis mellifera, an economically and agriculturally crucial insect species, for the development of a new array of insect control products based on behavior alteration. Inscent's honeybee repellent project was originally funded by the Citrus Research Board (CRB;, a coalition of California growers at the global forefront of citrus industry-funded scientific research.

The honeybee, Apis mellifera, is critical to US agriculture, and a Cornell University study estimated the direct value of honeybee pollination in this country exceeds $14 billion annually. Although the initial use of the repellent will be to prevent seediness in mandarins, it will also provide a solution for keeping bees out of fields that have been treated with insecticides. Honeybees are threatened by insecticide use and recent incidents of colony collapse have caused great concern among the farming and apiculture industries. These factors have combined to generate an urgent need for effective products that are safe to humans and insects alike.

Inscent, Inc. has developed a number of novel platform technologies to exploit the wide variety, selectivity, and high sensitivity of insect chemosensory systems. This proprietary collection of chemosensory proteins is being used to develop a series of non-toxic, highly efficient insect pest control products. Inscent's new technologies are applicable to a wide array of insect pest species that impact the agricultural, domestic, and public health sectors. Inscent's platform technologies utilize the latest developments in molecular genetics, genomics, and bioinformatics to design advanced, environmentally responsible insect pest control solutions and effective, sensitive biosensors. Further information on Inscent is available on the web at

The National Science Foundation is an independent federal agency that supports fundamental research and education across all fields of science and engineering. NSF also encourages scientific innovation and discovery in the commercial sector, primarily through the Small Business Innovative Research (SBIR) program. Further information on NSF is available on the web at

Inscent, Inc. welcomes inquiries from qualified investors and potential strategic allies.

SOURCE Inscent, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
2. DaVita Receives Civil Complaint
3. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
4. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
5. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
6. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
7. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
8. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
9. Prime Therapeutics Receives TIPPS Certification
10. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
11. UCLA receives $22.5 million to explore the fundamental biology of mental disorders
Post Your Comments:
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
(Date:6/24/2016)... ... , ... Comfort Keepers® of San Diego, CA is excited to announce they ... to drive cancer patients to and from their cancer treatments. Comfort Keepers provides ... life and ongoing independence. Getting to and from medical treatments is one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
Breaking Medicine Technology: